HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors.

Abstract
Salmosin is a novel disintegrin containing the Arg-Gly-Asp sequence that significantly inhibits platelet aggregation, basic fibroblast growth factor-induced endothelial cell proliferation, and tumor progression by antagonizing integrin-mediated cell interactions. Previously, it was shown that daily administration of salmosin was able to inhibit tumor-derived angiogenesis and adherence and proliferation of tumor cells, resulting in suppression of tumor progression. However, it is very difficult to maintain a therapeutic level of salmosin in the blood by systemic administration of the protein. Hence, an alternative strategy for antiangiogenic cancer therapy, based on the in vivo expression of the salmosin gene administered with cationic liposomes, was investigated. The salmosin peptides expressed in vitro inhibited the proliferation of bovine capillary endothelial cells in a dose-dependent manner, presumably as a result of inhibition of cell adhesion mediated via alpha(v)beta(3) integrin. Subcutaneous administration of the salmosin gene resulted in systemic expression of the gene product and concomitant inhibition of the growth of B16BL6 melanoma cells. Suppression of pulmonary metastases, verified by experimental and spontaneous metastasis models in mice, also resulted from salmosin gene treatment. These results suggest that administration of the salmosin gene complexed to cationic liposomes is effective in maintaining antiangiogenic salmosin at an effective therapeutic level and may be clinically applicable to anticancer gene therapy.
AuthorsSoo In Kim, Keun Sik Kim, Hong Sung Kim, Doo Sik Kim, Yangsoo Jang, Kwang Hoe Chung, Yong Serk Park
JournalCancer research (Cancer Res) Vol. 63 Issue 19 Pg. 6458-62 (Oct 01 2003) ISSN: 0008-5472 [Print] United States
PMID14559837 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cations
  • Crotalid Venoms
  • DNA, Complementary
  • Fatty Acids, Monounsaturated
  • Liposomes
  • Quaternary Ammonium Compounds
  • Recombinant Proteins
  • salmosin
  • Fibroblast Growth Factor 2
  • 1,2-dioleoyloxy-3-(trimethylammonium)propane
Topics
  • Animals
  • Cations
  • Cell Division (genetics, physiology)
  • Crotalid Venoms (biosynthesis, genetics)
  • DNA, Complementary (administration & dosage, genetics)
  • Fatty Acids, Monounsaturated (administration & dosage)
  • Female
  • Fibroblast Growth Factor 2 (antagonists & inhibitors, physiology)
  • Genetic Therapy (methods)
  • Humans
  • Liposomes (administration & dosage)
  • Melanoma, Experimental (genetics, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred ICR
  • Quaternary Ammonium Compounds (administration & dosage)
  • Recombinant Proteins (biosynthesis, genetics)
  • Transfection (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: